Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + topotecan
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Apatinib + topotecan is a combination therapy being investigated for the second-line treatment of relapsed or progressive small cell lung cancer (SCLC). Apatinib is a small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor-2 (VEGFR-2), thereby inhibiting tumor angiogenesis. Topotecan is a cytotoxic chemotherapy agent that acts as a topoisomerase I inhibitor, interfering with DNA replication and inducing cell death. This combination is being evaluated in clinical trials, such as those led by the First Hospitals affiliated to the China PLA General Hospital, to determine if the addition of an anti-angiogenic agent enhances the efficacy of standard second-line chemotherapy in SCLC patients who have failed prior platinum-based treatments.
- Other names
- Apatinib Plus Topotecan
02
Targets
TOP1 (DNA Topoisomerase I)ABCB1 (P-glycoprotein)ABCG2 (Breast cancer resistance protein)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on apatinib + topotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + topotecan.